Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ353MR)

This product GTTS-WQ353MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ALB&IL6R gene. The antibody can be applied in Inflammatory conditions, Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3570
UniProt ID P02768; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ353MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6153MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ9634MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ5026MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ10122MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ15038MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ5310MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ11259MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ2703MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW